Patent Leaderboard
USPTO Patent Rankings Data through Dec 31, 2025
Home › Heterodimeric antibodies that bind CD3 and tumor antigens

Heterodimeric antibodies that bind CD3 and tumor antigens

US Patent 11225528 · Granted Jan 18, 2022

Estimated economic value: $9,695,000 ⓘ

Assignee

Inventors

View full patent text on Google Patents →

More Patents by These Inventors

LAG-3 targeted heterodimeric fusion proteins containing IL-15/IL-15RA Fc-fusion 2025
LAG-3 targeted heterodimeric fusion proteins containing IL-15/IL-15RA Fc-fusion 2025
LAG-3 targeted heterodimeric fusion proteins containing IL-15/IL-15RA Fc-fusion 2025
Methods and compositions for inhibiting CD32B expressing cells in IGG4-related d2025
Methods and compositions for inhibiting CD32B expressing cells in IGG4-related d2025
Methods and compositions for inhibiting CD32B expressing cells in IGG4-related d2025
Anti-human C5 antibodies2025
Method of manufacturing diester-based compound2025
CTLA4-Ig immunoadhesins2025
Heterodimeric human IgG1 polypeptides with isoelectric point modifications2025
Targeted heterodimeric Fc fusion proteins containing NKG2D antigen binding domai2025
Targeted heterodimeric Fc fusion proteins containing NKG2D antigen binding domai2025